openPR Logo
Press release

Low Grade Glioma Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene

05-21-2024 09:14 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Low Grade Glioma Market to Register Incremental Growth During

DelveInsight's "Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Low Grade Glioma Market Report:
• The Low Grade Glioma market size was valued approximately USD 1 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2022, the market size of low-grade glioma (LGG) in Japan is below USD 100 million, with an anticipated increase during the forecast period from 2024 to 2034.
• In April 2024, Day One Biopharmaceuticals obtained accelerated approval from the FDA for tovorafenib, to be marketed as Ojemda, for managing relapsed or refractory pediatric low-grade glioma in patients aged six months and above. As per Ojemda's label, the oral kinase inhibitor is recommended for patients with verified BRAF fusion or rearrangement alterations, or a BRAF V600 mutation. The medication is available in tablet and oral suspension forms and should be administered once weekly.
• In October 2023, Day One Biopharmaceuticals revealed that the FDA has approved its NDA for tovorafenib as a standalone treatment for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has prioritized the review and set a target action date under the Prescription Drug User Fee Act (PDUFA) for April 30, 2024.
• In March 2023, The FDA has authorized the combination of TAFINLAR with MEKINIST, developed by Novartis, for pediatric patients aged 1 year and above diagnosed with low-grade glioma (LGG) and harboring a BRAF V600E mutation necessitating systemic treatment.
• In the seven major markets (7MM), the overall incident population of low-grade glioma (LGG) was estimated to be around 9,000 cases in 2022 and is expected to rise over the forecast period.
• In 2022, the United States had an estimated incident population of nearly 4,000 cases of low-grade glioma (LGG). This accounts for the largest portion of the incident population of LGG in the seven major markets (7MM), constituting approximately 40% of the total.
• In 2022, approximately 3,000 patients in the United States were identified with IDH mutation, while nearly 300 were diagnosed with BRAF V600E cases.
• Key Low Grade Glioma Companies: Day One Biopharmaceuticals, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
• Key Low Grade Glioma Therapies: Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
• The Low Grade Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.

Low Grade Glioma Overview
Low-grade Gliomas (LGG) constitute a diverse category of primary brain tumors commonly found in younger, otherwise healthy individuals. Typically, these tumors exhibit a relatively slow progression and extended survival rates compared to high-grade gliomas.

Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Low Grade Glioma Epidemiology Segmentation:
The Low Grade Glioma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Low Grade Glioma
• Prevalent Cases of Low Grade Glioma by severity
• Gender-specific Prevalence of Low Grade Glioma
• Diagnosed Cases of Episodic and Chronic Low Grade Glioma

Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Low Grade Glioma Therapies and Key Companies
• Tovorafenib: Day One Biopharmaceuticals
• Vinblastine: The Hospital for Sick Children
• Everolimus: University of California
• DAY101: Day One Biopharmaceuticals
• DS-1001b: Daiichi Sankyo Co.
• Mebendazole: Julie Krystal
• dabrafenib: Novartis
• Vorasidenib: Servier
• Mirdametinib: SpringWorks Therapeutics
• AB-218: AnHeart Therapeutics
• BGB-290: Beigene
• Infigratinib: Helsinn
• FT-2102 (Olutasidenib): Forma Therapeutics
• Vinblastine + Bevacizumab: Hoffmann-La Roche, and others

Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Low Grade Glioma Market Strengths
• Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Low Grade Glioma Market Opportunities
• Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.

Scope of the Low Grade Glioma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Low Grade Glioma Companies: Day One Biopharmaceuticals, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
• Key Low Grade Glioma Therapies: Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
• Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
• Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Low Grade Glioma Unmet Needs, KOL's views, Analyst's views, Low Grade Glioma Market Access and Reimbursement

To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/low-grade-glioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Low Grade Glioma Market Report Introduction
2. Executive Summary for Low Grade Glioma
3. SWOT analysis of Low Grade Glioma
4. Low Grade Glioma Patient Share (%) Overview at a Glance
5. Low Grade Glioma Market Overview at a Glance
6. Low Grade Glioma Disease Background and Overview
7. Low Grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Low Grade Glioma
9. Low Grade Glioma Current Treatment and Medical Practices
10. Low Grade Glioma Unmet Needs
11. Low Grade Glioma Emerging Therapies
12. Low Grade Glioma Market Outlook
13. Country-Wise Low Grade Glioma Market Analysis (2020-2034)
14. Low Grade Glioma Market Access and Reimbursement of Therapies
15. Low Grade Glioma Market Drivers
16. Low Grade Glioma Market Barriers
17. Low Grade Glioma Appendix
18. Low Grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Low Grade Glioma Epidemiology https://www.delveinsight.com/report-store/low-grade-glioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Low Grade Glioma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Low Grade Glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Report Offered By DelveInsight:

Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast till 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.

Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Low Grade Glioma Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Day One Biopharma, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene here

News-ID: 3506784 • Views:

More Releases from DelveInsight Business Research

Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Pfizer, AstraZeneca, Sermonix Pharmaceuticals, Novartis
Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epide …
(Albany, USA) DelveInsight's "Breast Cancer Biomarker Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Breast Cancer Biomarker, historical and forecasted epidemiology as well as the Breast Cancer Biomarker market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Breast Cancer Biomarker market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, C …
(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market. The Interstitial Lung Disease
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechan …
(Albany, USA) As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Myopia Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis

All 5 Releases


More Releases for Glioma

Growth Dynamics of Adult Malignant Glioma Therapeutics Market
Increasing Prevalence of malignant glioma is a key factor driving the adult malignant glioma therapeutics market, says Fortune Business Insights in a report, titled "Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026." The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million
Malignant Glioma Market Trends & Projection to 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons
Optic Nerve Glioma Market Global Analysis & Forecast to 2023
Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma are types of brain tumour primarily affecting the optic nerve cells. Optic nerve gliomas are slow growing, rare and mostly found in children. Its occurrence in individuals over age 20 is quite rare and any occurrence is associated with the genetic disorder neurofibromatosis type 1, or NF1 in approximately 30% of the cases. Symptoms of an optic nerve glioma are
Malignant Glioma Market to Significant Growth Foreseen by 2022
Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where children are less likely to develop the risk of gliomas. Gliomas arise from the glial cells or non-neuronal cells hence the name and the cells are supposed to provide support and protection for neurons
Malignant Glioma Pipeline Insight and Therapeutic Assessment 2017
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Malignant Glioma-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Malignant Glioma. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Malignant Glioma by development stage, therapy type, route of
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there